Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 33 AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 33 AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides a source of carbohydrates for caloric support; sodium chloride and potassium chloride provide electrolytes for maintenance of fluid and electrolyte balance. Potassium is essential for nerve conduction, muscle contraction, and acid-base balance.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous infusion: 500-1000 mL over 2-6 hours, rate dependent on fluid and electrolyte status; typical maintenance: 1-2 mL/kg/hour.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Glucose: ~1-2 hours (rapid clearance). Sodium and potassium: no true half-life; regulated by renal function. Clinical context: IV infusion effects decay rapidly upon cessation due to redistribution and metabolism.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Glucose: primarily metabolized to CO2 and water; renal excretion negligible. Sodium: >90% renal. Potassium: ~90% renal, 10% fecal. Chloride: primarily renal.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte